This inventor holds 2 USPTO granted patents and 2 published patent applications. Top assignee: Denali Therapeutics Inc.. Active years: 2022-2023.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022-2023
Title: Rinkan Shukla: Innovator in Neurodegenerative Disease Research
Introduction
Rinkan Shukla is a prominent inventor based in South San Francisco, CA, known for his significant contributions to the field of neurodegenerative diseases. With a focus on developing innovative therapeutic solutions, he has been instrumental in advancing research related to amyloid-beta and Tau proteins.
Latest Patents
Rinkan Shukla holds 2 patents that showcase his expertise in antibody development. His latest patents include "Anti-BACE1 antibodies and methods of use thereof," which details antibodies that specifically bind to the human BACE1 protein. These antibodies are designed to reduce effector function, extend serum stability, and promote heterodimerization. Additionally, the patent outlines methods for inhibiting amyloid-beta formation and treating neurodegenerative diseases. Another significant patent is "Anti-Tau antibodies and methods of use thereof," which describes antibodies that bind to various epitopes of the human Tau protein. This patent emphasizes the potential of these antibodies in recognizing both phosphorylated and unphosphorylated forms of Tau, contributing to the understanding and treatment of neurodegenerative conditions.
Career Highlights
Rinkan Shukla is currently associated with Denali Therapeutics Inc., a company dedicated to developing therapies for neurodegenerative diseases. His work at Denali Therapeutics has positioned him as a key player in the biotechnology sector, focusing on innovative solutions for complex neurological disorders.
Collaborations
Throughout his career, Rinkan has collaborated with notable colleagues, including Adam P Silverman and Mark S Dennis. These collaborations have further enriched his research and development efforts in the field of neurodegenerative disease therapies.
Conclusion
Rinkan Shukla's contributions to the field of neurodegenerative diseases through his innovative patents and collaborations highlight his commitment to advancing medical science. His work continues to pave the way for new therapeutic approaches that may significantly impact patient care in the future.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile